- Home
- CRBP vs RENB Comparison
CRBP vs RENB Comparison
Compare CRBP & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- RENB
- Stock Information
- Founded
- CRBP 2009
- RENB 2011
- Country
- CRBP United States
- RENB United States
- Employees
- CRBP N/A
- RENB N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- CRBP Health Care
- RENB Health Care
- Exchange
- CRBP Nasdaq
- RENB Nasdaq
- Market Cap
- CRBP 73.4M
- RENB 61.0M
- IPO Year
- CRBP N/A
- RENB N/A
- Fundamental
- Price
- CRBP $6.45
- RENB $0.32
- Analyst Decision
- CRBP Strong Buy
- RENB
- Analyst Count
- CRBP 10
- RENB 0
- Target Price
- CRBP $53.56
- RENB N/A
- AVG Volume (30 Days)
- CRBP 147.8K
- RENB 683.6K
- Earning Date
- CRBP 05-06-2025
- RENB 05-19-2025
- Dividend Yield
- CRBP N/A
- RENB N/A
- EPS Growth
- CRBP N/A
- RENB N/A
- EPS
- CRBP N/A
- RENB N/A
- Revenue
- CRBP N/A
- RENB N/A
- Revenue This Year
- CRBP N/A
- RENB N/A
- Revenue Next Year
- CRBP $150.00
- RENB N/A
- P/E Ratio
- CRBP N/A
- RENB N/A
- Revenue Growth
- CRBP N/A
- RENB N/A
- 52 Week Low
- CRBP $4.64
- RENB $0.29
- 52 Week High
- CRBP $61.90
- RENB $2.34
- Technical
- Relative Strength Index (RSI)
- CRBP 46.87
- RENB 37.38
- Support Level
- CRBP $6.10
- RENB $0.29
- Resistance Level
- CRBP $8.07
- RENB $0.35
- Average True Range (ATR)
- CRBP 0.71
- RENB 0.05
- MACD
- CRBP -0.10
- RENB 0.01
- Stochastic Oscillator
- CRBP 13.31
- RENB 18.83
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.